News
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...
The failure of Roche's tiragolumab in the SKYSCRAPER-01 trial in on-small cell lung cancer (NSCLC) has cast a pall over the TIGIT class, but iTeos said it is committed with GSK to completing their ...
Story May 28 - iTeos Therapeutics: After GSK axed its TIGIT partnership with the biotech, iTeos has decided to wind down operations and sell off its assets. At the end of last year, the biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback